Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus FLUOXYMESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus FLUOXYMESTERONE.
DANOCRINE vs FLUOXYMESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Category C
Category C
Androgen/Antigonadotropin
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."